Hope for Treating Relapse to Methamphetamine Abuse
Vigabatrin shown to block reinstatement of drug-seeking behavior
November 13, 2008
UPTON, NY — A new study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory suggests that vigabatrin (a.k.a. gamma vinyl-GABA, or GVG) blocks drug-seeking behavior in animals previously trained to associate methamphetamine with a particular environment. Specifically, animals pre-treated with vigabatrin lost interest in spending time in a location where they had previously been given methamphetamine. The results will appear in the February 2009 issue of Synapse, now available online.
Stephen Dewey (right) and Amy DeMarco
“Reinstatement of drug-seeking behavior after an extended period of abstinence is the number-one cause of drug-addiction relapse,” said Brookhaven neuroanatomist Stephen Dewey, who led the research team. “This animal study suggests that vigabatrin could potentially prevent human methamphetamine addicts from relapsing.”
According to the National Institute on Drug Abuse, methamphetamine is a very addictive stimulant that is quickly becoming an American public health epidemic. There is currently no effective treatment for methamphetamine addiction.
Vigabatrin is a pharmaceutical agent first tested as a possible treatment for a variety of addictions in animal studies led by Dewey at Brookhaven Lab (http://www.bnl.gov/CTN/GVG/). It is the only drug that has been shown to block any behavior associated with methamphetamine use, and is currently being tested by Catalyst Pharmaceutical Partners (http://www.catalystpharma.com/) for safety and efficacy against cocaine and methamphetamine addiction in humans in Phase II clinical trials across the U.S.
“In human drug abusers, many things can cause relapse — exposure or access to drugs, environmental cues that trigger thoughts of the drug, or stress,” said Dewey. “If vigabatrin can prevent relapse, it could have a huge impact by helping drug abusers regain control over their lives.”
In the current study, rats were first put through a series of conditioning tests that taught them to expect methamphetamine in one chamber of a three-chamber apparatus and saline solution in another chamber. The researchers then allowed the rats to roam freely among the three chambers. If the rats spent the majority of their time in the chamber where they had been given methamphetamine, the scientists knew they had established a “conditioned place preference.”
Once this preference was established, the researchers extinguished it by giving the rats saline injections in both chambers, again allowing the animals to have free access to all chambers until the rats had no preference for the previously methamphetamine-associated chamber for at least six consecutive days.
Once extinguished, however, it is possible for a conditioned preference to be reinstated — just as it is possible for a recovered drug addict to relapse. To reinstate the place preference in this experiment, Brookhaven scientists injected the rats with methamphetamine in the neutral chamber. Immediately, rats went to the chamber where they had received methamphetamine and remained there for the duration of the exposure period.
Then, once the reinstatement of a preference was clearly demonstrated, the researchers tested the effectiveness of vigabatrin at blocking it. They pre-treated animals with vigabatrin two-and-a-half hours before giving them another priming dose of methamphetamine followed by free access to all three chambers. When pre-treated with vigabatrin, the rats no longer showed any preference for one chamber over another.
Dewey’s group is now conducting studies to examine whether GVG will also block an environmental cue previously shown to produce relapse to drug-seeking behavior.
“These studies have wide implications for addressing the number-one cause of relapse to drug seeking behavior. If we can successfully block drug-induced reinstatement, then our ability to block environmental cue-induced relapse is significantly enhanced,” Dewey said.
Collaborators on this study included: Amy DeMarco, now an M.D./Ph.D. student at Stony Brook University, who conducted the research while working in Dewey's lab at Brookhaven last summer and is lead author on the paper; Reema Dalal, Jessica Pai, and Jonathan Brodie of New York University; Stefanie Aquilina of Cornell University; Uma Mullapudi of Dartmouth College; Shiva Kothari of Duke University; Milan Kahanda of Rensselaer Polytechnic Institute; Crystie Hammel of Stony Brook University; and Courtney Liebling, Vinal Patel, and Wynne Schiffer of Brookhaven Lab. The research was funded by the National Institute on Drug Abuse and the Office of Biological and Environmental Research of DOE's Office of Science.
DOE’s Brookhaven Lab has a world-renowned research program aimed at understanding the neurological mechanisms and consequences of drug addiction and other addictive behaviors. This program is fueled, in part, by DOE’s long-standing support of brain-imaging technologies developed as a direct outgrowth of their commitment to basic physics and nuclear chemistry research.
All research involving laboratory animals at Brookhaven National Laboratory is conducted under the jurisdiction of the Lab’s Institutional Animal Care and Use Committee in compliance with the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals, the U.S. Department of Agriculture’s Animal Welfare Act, and the National Academy of Sciences’ Guide for the Care and Use of Laboratory Animals. This research has enhanced understanding of a wide array of human medical conditions including cancer, drug addiction, Alzheimer’s and Parkinson’s diseases, and normal aging and has led to the development of several promising treatment strategies.
For more information on methamphetamine, click here
2008-10854 | INT/EXT | Newsroom